February 9, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Technology
100 F Street NE
Washington, D.C. 20549
Attention: Brian Fetterolf
Re: | Sunshine Biopharma, Inc. |
Registration Statement on Form S-1, as amended File No. 333-259394 | |
Initially Filed September 9, 2021 |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Sunshine Biopharma, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to accelerate the effective date of the above-referenced registration statement (the “Registration Statement”) so as to become effective on Friday, February 11, 2022, at 4:30 p.m. Eastern Time, or as soon thereafter as practicable. Once the Registration Statement has been declared effective, please confirm orally that event with our counsel, Sichenzia Ross Ference LLP., by calling Jeff Cahlon at 212-930-9700.
Very truly yours, | |
/s/ Dr. Steve N. Slilaty | |
Dr. Steve N. Slilaty | |
Chief Executive Officer |